Multi-Disciplinary Organization Dedicated to Promoting Advances in
Neuro-Oncology Through Research and Education

WFNOS Magazine

The inaugural issue of the official publication of the World Federation of Neuro-Oncology Societies is ...

Read Full Story

Neuro-Oncology Review Course at SNO

November 16, 2016. Register in conjunction with the SNO Annual Meeting

Read Full Story

CNS Anticancer Drug Discovery and Development Conference

Register Now!

Read Full Story
View All News

October
12

EANO 2016

Read Full Story

October
22

18th Annual Brain Tumor Update and 7th Annual International Symposium on Long-Term Control of Metastases to the Brain and Spine

Read Full Story

November
16

2nd CNS Anticancer Drug Discovery/Development Conference

Read Full Story

2011 Neuro-Tumor Club Dinner Program

17th ANNUAL NEURO TUMOR CLUB DINNER MEETING
HOSTED BY THE SOCIETY FOR NEURO-ONCOLOGY

ROSEN CENTRE HOTEL
9840 International Drive
Orlando, Florida 32819

MONDAY, APRIL 04, 2011 6:30PM – 10:00PM


6:30-7:00 Buffet Dinner Service

7:00-7:05 Introductions and Acknowledgments
Waldemar Debinski
, Wake Forest University, and Hideho Okada, University of Pittsburgh


Session 1: Geno/Phenotyping and Personalized/Combinatorial Therapy
7:05-7:10 Overview: Michael D. Taylor, University of Toronto, Canada

7:10-7:15 1 Irene Vassallo, Chuv, Lausanne, France
The Wnt inhibitory Factor 1 has tumor suppressing functions in glioblastoma potentially by inducing cellular senescence

7:20-7:25 2 Lonneke A.M. Gravendeel, Erasmus MC, Rotterdam, the Netherlands
Tetraploid gliomas share molecular features with pilocytic astrocytomas

7:30-7:35 3 Marc Remke, German Cancer Research Center, Heidelberg, Germany
Integrated genomic approach indicates three major molecular variants in adult medulloblastoma

7:40-7:45 4, Huriye Cin, German Cancer Research Center, Heidleberg, Germany
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises and alternative mechanism of MAPK pathway activation in pilocytic astrocytoma


Session 2: Angiogenesis and Tumor Microenvironment
7:50-7:55 Overview: Linda J. Metheny-Barlow, Wake Forest University, Winston-Salem, NC

7:55-8:00 5 Yvan Chanthery, UCSF, San Francisco, CA
Paracrine signaling through Mycn enhances tumor-vascular interactions in neuroblastoma

8:05-8:10 6 Daniel J. Brat, Emory University, Atlanta, GA
Integrated analysis of necrosis, angiogenesis, and gene expression in glioblastoma

8:15-8:20 7 Maria Castro, Gene Therapeutics Research Institute, UCLA, Los Angeles, CA
Glioma-derived factors induce the expansion of myeloid-derived suppressor cells (MDSCs) that facilitate immune suppression and tumor progression


Session 3: New Tools and Translational Science
8:25-8:30 Overview: John Park, National Institutes of Health, Bethesda, MD

8:30-8:35 8 Zach Reitman, Duke University Medical Center, Raleigh, NC
Global and targeted approaches to analyze the glioma metabolome

8:40-8:45 9 Oscar A. Gonzales, Wake Forest University, Winston-Salem, NC
EphA2/eprhinA1: A potential role in invadopodia formation in GBM cells

8:50-8:55 10 Ji Young Yoo, Ohio State University, Columbus, OH
Anti-tumor efficacy of 34.5ENVE: A transcriptionally retargeted and “Vstat120” expressing oncolytic virus

9:00-9:05 11 Jan Gronych, German Cancer Research Center, Heidelberg, Germany
An activated BRAF induces pilocytic astrocytoma in mice

 

Session 4: New Gene and Immunotherapy
9:10-9:15 Overview: John Ohlfest, University of Minnesota, Minneapolis, MN

9:15-9:20 12 Xinggang Mao, Johns Hopkins University School of Medicine, Baltimore, MD
LIN28 promotes glioblastoma tumorgenicity through upregulation of HMGA2

9:25-9:30 13 Katherine Murphy, University of Minnesota, Minneapolis, MN
Enhanced anti-tumor immunity through OX40L signaling requires B cells

9:35-9:40 14 Veronique Frattini, IRCCS Foundation Neurological Institute, Milan, Italy
FOXP3, a candidate tumor suppressor for glioblastoma, inhibits proliferation and migration by inducing differentiation in glioma stem-like cells

9:45-10:00 Mingle together and more discussion

NOTE: Each talk is 5 minutes, followed by a 5 minute discussion

To RSVP for the meeting, click here.